JP5752419B2 - 新規ヒト転移性腫瘍関連分子、活性化遺伝子およびタンパク質を検出する方法ならびに遺伝子発現を妨害する方法 - Google Patents

新規ヒト転移性腫瘍関連分子、活性化遺伝子およびタンパク質を検出する方法ならびに遺伝子発現を妨害する方法 Download PDF

Info

Publication number
JP5752419B2
JP5752419B2 JP2010543378A JP2010543378A JP5752419B2 JP 5752419 B2 JP5752419 B2 JP 5752419B2 JP 2010543378 A JP2010543378 A JP 2010543378A JP 2010543378 A JP2010543378 A JP 2010543378A JP 5752419 B2 JP5752419 B2 JP 5752419B2
Authority
JP
Japan
Prior art keywords
tucap
cells
protein
seq
melanoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010543378A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011511625A (ja
JP2011511625A5 (https=
Inventor
フランチェスコ・ロツポーネ
ステファノ・ファイス
Original Assignee
ハンサビオメド・オサウヒング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハンサビオメド・オサウヒング filed Critical ハンサビオメド・オサウヒング
Publication of JP2011511625A publication Critical patent/JP2011511625A/ja
Publication of JP2011511625A5 publication Critical patent/JP2011511625A5/ja
Application granted granted Critical
Publication of JP5752419B2 publication Critical patent/JP5752419B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2010543378A 2008-01-25 2009-01-26 新規ヒト転移性腫瘍関連分子、活性化遺伝子およびタンパク質を検出する方法ならびに遺伝子発現を妨害する方法 Expired - Fee Related JP5752419B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6245308P 2008-01-25 2008-01-25
US61/062,453 2008-01-25
PCT/EE2009/000001 WO2009092385A1 (en) 2008-01-25 2009-01-26 A new metastatic human tumor associated molecule, methods to detect both activated gene and protein and to interfere with gene expression

Publications (3)

Publication Number Publication Date
JP2011511625A JP2011511625A (ja) 2011-04-14
JP2011511625A5 JP2011511625A5 (https=) 2012-02-16
JP5752419B2 true JP5752419B2 (ja) 2015-07-22

Family

ID=40527972

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010543378A Expired - Fee Related JP5752419B2 (ja) 2008-01-25 2009-01-26 新規ヒト転移性腫瘍関連分子、活性化遺伝子およびタンパク質を検出する方法ならびに遺伝子発現を妨害する方法

Country Status (12)

Country Link
US (1) US8097407B2 (https=)
EP (1) EP2245465B1 (https=)
JP (1) JP5752419B2 (https=)
CN (1) CN102016587B (https=)
AU (1) AU2009207926B2 (https=)
BR (1) BRPI0906681A2 (https=)
CA (1) CA2713193C (https=)
ES (1) ES2587055T3 (https=)
MX (1) MX2010008163A (https=)
PL (1) PL2245465T3 (https=)
RU (1) RU2546000C2 (https=)
WO (1) WO2009092385A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120122118A1 (en) * 2008-01-25 2012-05-17 Primm Srl Monclonal antibodies, hybridomas and methods for use
EP2467392A4 (en) * 2009-08-17 2013-06-19 Nox Technologies Inc CLONING AND EXPRESSION OF 9-DOMAIN SUPERFAMILY OF ARNOX TRANSMEMBRANE PROTEINS, METHODS AND UTILITY
JP6187939B2 (ja) * 2012-03-08 2017-08-30 学校法人産業医科大学 がんの悪性度の試験方法、ならびに多能性を有する造腫瘍細胞およびその調製方法
WO2015185730A2 (en) * 2014-06-06 2015-12-10 Hansabiomed Ou Exosomal biomarkers
CN105675378A (zh) * 2014-11-18 2016-06-15 上海张江转化医学研发中心有限公司 一种简单的分离单个循环肿瘤细胞的方法和装置
JP6573351B2 (ja) 2017-05-29 2019-09-11 国立大学法人神戸大学 検出対象の分析用センサ作製用基材、検出対象の分析用センサ、及び検出対象の分析法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030175787A1 (en) * 1997-10-28 2003-09-18 Incyte Corporation Vesicle membrane proteins
US20030008356A1 (en) * 1998-08-07 2003-01-09 Ono Pharmaceutical Co., Ltd. Novel polypeptide, a cDNA encoding the same, and use of it
WO2000008056A1 (fr) * 1998-08-07 2000-02-17 Ono Pharmaceutical Co., Ltd. NOUVEAU POLYPEPTIDE, ADNc LE CODANT ET SON UTILISATION
US20070224201A1 (en) * 2002-10-02 2007-09-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2005108415A2 (en) * 2004-04-30 2005-11-17 Biogen Idec Ma Inc. Membrane associated molecules
WO2006110593A2 (en) * 2005-04-07 2006-10-19 Macrogenics, Inc. Biological targets for the diagnosis, treatment and prevention of cancer

Also Published As

Publication number Publication date
EP2245465A1 (en) 2010-11-03
AU2009207926B2 (en) 2014-06-19
PL2245465T3 (pl) 2016-11-30
US20090191222A1 (en) 2009-07-30
RU2546000C2 (ru) 2015-04-10
EP2245465B1 (en) 2016-05-18
MX2010008163A (es) 2011-04-26
ES2587055T3 (es) 2016-10-20
JP2011511625A (ja) 2011-04-14
US8097407B2 (en) 2012-01-17
CN102016587B (zh) 2015-05-13
CA2713193A1 (en) 2009-07-30
RU2010135525A (ru) 2012-02-27
BRPI0906681A2 (pt) 2019-11-26
WO2009092385A1 (en) 2009-07-30
CA2713193C (en) 2018-01-02
CN102016587A (zh) 2011-04-13
AU2009207926A1 (en) 2009-07-30

Similar Documents

Publication Publication Date Title
US9316654B2 (en) TAZ/WWTR1 for diagnosis and treatment of cancer
JP2021006039A (ja) ヒト非小細胞肺癌における転座及び変異体ｒｏｓキナーゼ
JP5752419B2 (ja) 新規ヒト転移性腫瘍関連分子、活性化遺伝子およびタンパク質を検出する方法ならびに遺伝子発現を妨害する方法
KR20110005812A (ko) 항-글리피칸-3 항체를 사용하여 간암 세포를 검출하는 방법
WO2009050691A2 (en) Compositions comprising semaphorins for the treatment of angiogenesis related diseases and methods of selection thereof
KR100972618B1 (ko) 허셉틴을 이용한 유방암 진단 키트, 조성물 및 이들을이용하여 허셉틴 민감성 ｈｅｒ２ 과발현 세포를 검출하는방법
JP5893037B2 (ja) Ｂｒａｆｖ６００ｅに特異的に結合する抗体を使用する癌の診断のための手段及び方法
US20180313841A1 (en) Ovary Tumor Markers And Methods Of Use Thereof
US20070031419A1 (en) Methods and compositions for treating diseases targeting CDCP1
EP4522991B1 (en) Use of bmmf1 rep protein as diagnostic marker for lung cancer
EP4522990B1 (en) Use of bmmf1 rep protein as diagnostic marker for pancreatic cancer and diabetes mellitus type 2
KR101927577B1 (ko) 간암 바이오 마커로서 ｈ２ａ．ｚ．１의 용도
WO2006022682A2 (en) Method and compositions for treating diseases targeting cd49b
US8507213B1 (en) Methods and compositions for treating diseases targeting maba
JPWO2006082851A1 (ja) エピグリカニン関連ムチン
US20060039907A1 (en) Method and compositions for treating diseases targeting CD71
WO2004013634A2 (en) Dna damage repair polypeptide and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131203

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131210

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20131219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140106

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140114

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140203

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141201

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150421

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150520

R150 Certificate of patent or registration of utility model

Ref document number: 5752419

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees